Company profile: Nebula Genomics
1.1 - Company Overview
Company description
- Provider of blockchain-enabled whole genome sequencing (30x and 100x coverage) and a trusted genomic and health data marketplace that ensures consumer data control. Offers Nebula Explore reporting membership, a curated research library, genome exploration tools, and deep genetic ancestry using full mtDNA and Y-DNA sequencing.
Products and services
- 100x Whole Genome Sequencing: A DNA test that decodes 100% of your genome with 100x coverage, offering ultra-high accuracy and detailed insights into rare genetic variants
- 30x Whole Genome Sequencing: A DNA test decoding 100% of your genome with 30x coverage, delivering detailed health, ancestry, and genetic trait insights across your entire genome
- Nebula Explore Reporting Membership: A blockchain-enabled membership supplying personalized reports, access to genome exploration tools, and deep ancestry analysis based on your whole genome sequencing data
Key contacts
🔒
🔒
Financial details
🔒
1.2 - Competitors and similar companies to Nebula Genomics
Tavec Pharma
HQ: Canada
Website
- Description: Provider of injectable cancer therapies using exosome-mediated delivery technology. The company enables delivery by injection of anti-cancer molecules, including regulatory RNA, directly to cancer cells to disrupt growth and metastasis.
- Rationale: This competitor operates in a highly similar market segment with overlapping features.
- Company type: Private company
- Employees: ●●●●●
- Total funding raised: $●●●m
- Backers: ●●●●●●●●●●
- Acquisitions: ●●
View full Tavec Pharma company profile →
Sestina Bio
HQ: United States
Website
- Description: Provider of automated synthetic biology platforms and gene-editing tools to sustainably feed, clothe, and treat the world's population, including the GenoScaler™ Platform for automated synthetic biology and the MAD7® Nuclease for precise genome modifications.
- Rationale: This competitor operates in a highly similar market segment with overlapping features.
- Company type: Private company
- Employees: ●●●●●
- Total funding raised: $●●●m
- Backers: ●●●●●●●●●●
- Acquisitions: ●●
View full Sestina Bio company profile →
Singleron
HQ: China
Website
- Description: Provider of clinical diagnosis, health management, and drug development products and services, dedicated to applying single cell analysis techniques. Holds a worldwide exclusive IP license from Yale University for a uniquely designed microfluidic single cell processing device.
- Rationale: This competitor operates in a highly similar market segment with overlapping features.
- Company type: Private company
- Employees: ●●●●●
- Total funding raised: $●●●m
- Backers: ●●●●●●●●●●
- Acquisitions: ●●
View full Singleron company profile →
LaserGen
HQ: United States
Website
- Description: Provider of biotechnology technologies for genomics and sequencing applications, developing and commercializing tools that detect heritable and somatic sequence variations in the human genome for use as diagnostic tools.
- Rationale: This competitor operates in a highly similar market segment with overlapping features.
- Company type: Private company
- Employees: ●●●●●
- Total funding raised: $●●●m
- Backers: ●●●●●●●●●●
- Acquisitions: ●●
View full LaserGen company profile →
OPKO Health
HQ: United States
Website
- Description: Provider of pharmaceuticals and diagnostics based on novel proprietary technologies, including NGENLA, a once-weekly human growth hormone analog for pediatric growth failure due to inadequate endogenous growth hormone secretion, and RAYALDEE, an extended-release oral calcifediol for treating secondary hyperparathyroidism in adults with stage 3 or 4 chronic kidney disease and vitamin D insufficiency.
- Rationale: This competitor operates in a highly similar market segment with overlapping features.
- Company type: Private company
- Employees: ●●●●●
- Total funding raised: $●●●m
- Backers: ●●●●●●●●●●
- Acquisitions: ●●
View full OPKO Health company profile →
🔒
2.M&A buyers
2.1 Potential strategic acquirers in the sector
🔒
🔒
🔒
🔒
View all strategic buyers with complete profiles
Start Free Trial →
2.2 - Strategic buyer groups for Nebula Genomics
🔒
Buyer group 1: ████████ ████████
●● companies
Description: ████████ ████████ ████████ ████████ ████████ ████████ ████████ ████████ ████████ ████████
Key Products: ████████, ████████, ████████, ████████
🔒
View all companies in this group
Request Free Trial Now →
🔒
Buyer group 2: ████████ ████████
●● companies
Description: ████████ ████████ ████████ ████████ ████████ ████████ ████████ ████████ ████████ ████████
Key Products: ████████, ████████, ████████, ████████
🔒
View all companies in this group
Request Free Trial Now →
🔒
Buyer group 3: ████████ ████████
●● companies
Description: ████████ ████████ ████████ ████████ ████████ ████████ ████████ ████████ ████████ ████████
Key Products: ████████, ████████, ████████, ████████
🔒
View all companies in this group
Request Free Trial Now →
🔓 Unlock all detailed buyer group breakdowns with complete company profiles
Start Free Trial →
3. Investors and private equity firms
3.1 - Buyout funds investing in similar companies to Nebula Genomics
2.2 - Growth funds investing in similar companies to Nebula Genomics
🔒
View all growth equity funds with complete profiles
Start Free Trial →
4 - Top valuation comps for Nebula Genomics
4.2 - Public trading comparable groups for Nebula Genomics
🔓 Unlock all public trading comparable groups with complete valuation data
Start Free Trial →